Hepatitis drugs refers to medicinal drugs used in the treatment of various hepatitis infections. Hepatitis is a disease characterized by the inflammation of liver and has numerous causes, such as alcohol consumption, drug abusing, and viral infections. Several types of viruses are responsible for causing viral hepatitis, and the major types include A, B, C, D, and E. Type A, B, and C are the most common occurring hepatitis viruses. Every hepatitis virus causes different symptoms of disease and transmitted in numerous ways.
The symptoms of hepatitis generally do not occur in the first week after infection. However, when they occur, the symptoms of hepatitis type A, B and C may include nausea, fatigue, poor appetite, belly pain, mild fever, and jaundice. Hepatitis is diagnosed by various diagnostic procedures. The major procedures include liver biopsy, liver function tests, ultrasound, and blood tests.
The companies dealing in hepatitis drugs market are actively involved in collaborations and partnerships to provide novel therapeutic solutions for the treatment of hepatitis infections. Most of these collaboration and partnerships are focused on accelerating and streamlining the pharmaceutical drug development process, and providing a range of novel drugs for the management of various chronic diseases including hepatitis.
The hepatitis drugs market in Asia is expected to grow at a rapid rate. The various factors driving the growth of the Asian hepatitis drugs market include aging population, increasing prevalence of hepatitis, and improving healthcare infrastructure.
The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.
